Safety Assessment of an Anti-Obesity Drug (Sibutramine)A Retrospective Cohort Study

被引：0
|
作者：
Jerzy E. Tyczynski
Denise M. Oleske
David Klingman
Cheryl P. Ferrufino
Won Chan Lee
机构：
[1] Product Safety and Pharmacovigilance,Astellas Pharma Global Development, Inc.
[2] Global Surveillance and Pharmacoepidemiology,Abbott Laboratories
[3] Dept R4ED,Health Economics and Outcomes Research
[4] IMS Health Inc.,undefined
来源：
Drug Safety | 2012年 / 35卷 / 8期
关键词：
Acute Myocardial Infarction; Orlistat; Rimonabant; Sibutramine; Label Status;
D O I：
10.1007/BF03261960
中图分类号：
学科分类号：
摘要：
Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns over the potential of increased risk of cardiovascular (CV) events, based on a phase IV clinical trial that included only individuals at high risk for CV events.
引用
收藏
页码：629 / 644
页数：15
相关论文
共 50 条
  • [21] Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications
    Halpern, Bruno
    Halpern, Alfredo
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (02) : 305 - 315
  • [22] Tolerability and Safety of the New Anti-Obesity Medications
    Vojtech Hainer
    Irena Aldhoon-Hainerová
    Drug Safety, 2014, 37 : 693 - 702
  • [23] Cardiovascular Safety and Superiority of Anti-Obesity Medications
    Alobaida, Muath
    Alrumayh, Abdullah
    Oguntade, Ayodipupo S.
    Al-Amodi, Faez
    Bwalya, Mwango
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 3199 - 3208
  • [24] Anti-obesity drug discovery: advances and challenges
    Mueller, Timo D.
    Blueher, Matthias
    Tschoep, Matthias H.
    DiMarchi, Richard D.
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) : 201 - 223
  • [25] The effects of anti-obesity drug treatment on fibromyalgia
    Tamer, N
    Katyrcy, S
    Akkus, S
    Akta, K
    Tunç, E
    Özcankaya, R
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 504 - 504
  • [26] Anti-obesity drug discovery: advances and challenges
    Timo D. Müller
    Matthias Blüher
    Matthias H. Tschöp
    Richard D. DiMarchi
    Nature Reviews Drug Discovery, 2022, 21 : 201 - 223
  • [27] Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment
    Van Gaal, LF
    Wauters, MA
    De Leeuw, IH
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 : 35 - 39
  • [28] Rimonabant: more than an anti-obesity drug?
    Costa, B.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 150 (05) : 535 - 537
  • [29] An improved synthesis of Rimonabant: Anti-obesity drug
    Kotagiri, Vijay Kumar
    Suthrapu, Sashikanth
    Reddy, Jambula Mukunda
    Rao, Chitneni Prasad
    Bollugoddu, Vijaybhaskar
    Bhattacharya, Apurba
    Bandichhor, Rakeshwar
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2007, 11 (05) : 910 - 912
  • [30] US anti-obesity drug to hit market
    不详
    CHEMICAL ENGINEER-LONDON, 1996, (623): : 6 - 6
12345